UBR5在肿瘤发生发展中作用及其机制研究进展
Research Progress on the Role and Mechanism of UBR5 in Tumorigenesis and Development
DOI: 10.12677/ACM.2022.125703, PDF,   
作者: 王小兵：重庆渝北区人民医院普通外科(胃肠外科)，重庆；伍 阅, 李金昊, 龚建平：重庆医科大学附属第二医院肝胆外科，重庆
关键词: 泛素–蛋白酶体系统；UBR5；肿瘤；Ubiquitin-Protease System； UBR5； Tumor
摘要: 泛素蛋白酶系统(ubiquitin-proteasome system, UPS)是细胞信号转导和蛋白质稳定的重要调节因子，对多种细胞过程有着重要的作用。泛素蛋白链接酶E3识别素5，(ubiquitin protein ligase E3 component n-recognin 5, UBR5，又名EDD1)具有独特的结构特征，参与了DNA损伤反应、代谢、转录和凋亡的调节，在癌症和发育过程中成为UPS的关键调节因子。UBR5在癌症中的作用引起了科研人员的广泛关注。本文将从UBR5的结构、泛素化与E3泛素化连接酶的作用、UBR5在各种癌症中的作用及其作用机制进行综述。
Abstract: The ubiquitin-proteasome system (UPS) is an important regulator of cell signal transduction and protein stability, and plays an important role in a variety of cellular processes. Ubiquitin protein ligase E3 recognin 5, (ubiquitin protein ligase E3 component n-recognin 5, UBR5, also known as EDD1) has unique structural features and is involved in the regulation of DNA damage response, metabolism, transcription and apoptosis, and is involved in the regulation of DNA damage response, metabolism, transcription and apoptosis, and becomes a key regulator of the UPS during develop-ment. The role of UBR5 in cancer has attracted extensive attention from researchers. This article will review the structure of UBR5, the role of ubiquitination and E3 ubiquitination ligase, the role of UBR5 in various cancers and its mechanism of action.
文章引用：王小兵, 伍阅, 李金昊, 龚建平. UBR5在肿瘤发生发展中作用及其机制研究进展[J]. 临床医学进展, 2022, 12(5): 4853-4857. https://doi.org/10.12677/ACM.2022.125703

参考文献

[1] Johnson, D.E. (2015) The Ubiquitin-Proteasome System: Opportunities for Therapeutic Intervention in Solid Tumors. Endocrine-Related Cancer, 22, T1-17. [Google Scholar] [CrossRef] 
[2] Pal, A., Young, M.A. and Do-nato, N.J. (2014) Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer. Cancer Research, 74, 4955-4966. [Google Scholar] [CrossRef] 
[3] Bethard, J.R., Zheng, H., Roberts, L. and Eblen, S.T. (2011) Identification of Phosphorylation Sites on the E3 Ubiquitin Ligase UBR5/EDD. Journal of Proteomics, 75, 603-609. [Google Scholar] [CrossRef] [PubMed]
[4] Grau-Bové, X., Sebé-Pedrós, A. and Ruiz-Trillo, I. (2013) A Genomic Survey of HECT Ubiquitin Ligases in Eukaryotes Reveals Independent Expan-sions of the HECT System in Several Lineages. Genome Biology and Evolution, 5, 833-847. [Google Scholar] [CrossRef] [PubMed]
[5] Swenson, S.A., Gilbreath, T.J., Vahle, H., et al. (2020) UBR5 HECT Do-main Mutations Identified in Mantle Cell Lymphoma Control Maturation of B Cells. Blood, 136, 299-312. [Google Scholar] [CrossRef] [PubMed]
[6] Munoz-Escobar, J., Matta-Camacho, E., Kozlov, G. and Gehring, K. (2015) The MLLE Domain of the Ubiquitin Ligase UBR5 Binds to Its Catalytic Domain to Regulate Substrate Bind-ing. Journal of Biological Chemistry, 290, 22841- 22850. [Google Scholar] [CrossRef] 
[7] Wang, D., Xu, Q., Yuan, Q., Jia, M., Niu, H., Liu, X., et al. (2019) Proteasome Inhibition Boosts Autophagic Degradation of Ubiquitinated-AGR2 and Enhances the Antitumor Efficiency of Bevacizumab. Oncogene, 38, 3458-3474. [Google Scholar] [CrossRef] [PubMed]
[8] De Martino, L., Errico, M.E., Ruotolo, S., Cascone, D., Chiaraval-li, S., Collini, P., et al. (2018) Pediatric Lung Adenocarcinoma Presenting with Brain Metastasis: A Case Report. Journal of Medical Case Reports, 12, 243. [Google Scholar] [CrossRef] [PubMed]
[9] Dompe, N., et al. (2011) A Whole-Genome RNAi Screen Identi-fies an 8q22 Gene Cluster That Inhibits Death Receptor-Mediated Apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 108, E943-E951. [Google Scholar] [CrossRef] [PubMed]
[10] Bolt, M.J., Stossi, F., Callison, A.M., Mancini, M.G., Dandekar, R. and Mancini, M.A. (2014) Systems Level-Based RNAi Screening by High Content Analysis Identifies UBR5 as a Regulator of Estrogen Receptor-α Protein Levels and Activity. Oncogene, 34, 154-164. [Google Scholar] [CrossRef] [PubMed]
[11] Song, M., Wang, C., Wang, H., Zhang, T., Li, J., Benezra, R., et al. (2020) Targeting Ubiquitin Protein Ligase E3 Component N-Recognin 5 in Cancer Cells Induces a CD8+ T Cell Mediated Immune Response. Oncoimmunology, 9, Article ID: 1746148. [Google Scholar] [CrossRef] 
[12] Liao, L., Song, M., Li, X., Tang, L., Zhang, T., Zhang, L., et al. (2017) E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer. Cancer Re-search, 77, 2090-2101. [Google Scholar] [CrossRef] 
[13] Qiao, X., Liu, Y., Prada, M.L., Mohan, A.K., Gupta, A., Jaiswal, A., et al. (2020) UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Lim-its MYC-Dependent Apoptosis. Cancer Research, 80, 1414- 1427. [Google Scholar] [CrossRef] 
[14] Yang, Y., Zhao, J., Mao, Y., Lin, G., Li, F. and Jiang, Z. (2020) UBR5 Over-Expression Contributes to Poor Prognosis and Tamoxifen Resistance of ERa+ Breast Cancer by Stabilizing β-Catenin. Breast Cancer Research and Treatment, 184, 699-710. [Google Scholar] [CrossRef] [PubMed]
[15] Yang, M., Jiang, N., Cao, Q.-W., Ma, M.-Q. and Sun, Q. (2016) The E3 Ligase UBR5 Regulates Gastric Cancer Cell Growth by Destabilizing the Tumor Suppressor GKN1. Biochemical and Biophysical Research Communications, 478, 1624-1629. [Google Scholar] [CrossRef] [PubMed]
[16] Xie, Z., Liang, H., Wang, J., Xu, X., Zhu, Y., Guo, A., et al. (2017) Significance of the E3 Ubiquitin Protein UBR5 as an Oncogene and a Prognostic Biomarker in Colorectal Cancer. Oncotarget, 8, Article ID: 108079-92. [Google Scholar] [CrossRef] [PubMed]
[17] Eblen, S.T. and Bradley, A. (2017) MOAP-1, UBR5 and Cisplatin Resistance in Ovarian Cancer. Translational Cancer Research, 6, S18-S21. [Google Scholar] [CrossRef] [PubMed]
[18] Ji, S.Q., et al. (2017) UBR5 Promotes Cell Proliferation and Inhibits Apoptosis in Colon Cancer by Destablizing P21. Pharmazie, 72, 408-413.
[19] Wang, J., Zhao, X., Jin, L., Wu, G. and Yang, Y. (2017) UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4. Digestive Diseases and Sciences, 62, 2781-2789. [Google Scholar] [CrossRef] [PubMed]
[20] Leboeuf, D., Abakumova, T., Prikazchikova, T., Rhym, L. ander-son, D.G., Zatsepin, T.S., et al. (2020) Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chem-otherapy in Vivo. Molecular Therapy, 28, 1092-1104. [Google Scholar] [CrossRef] [PubMed]
[21] Zhang, Z., Zheng, X., Li, J., Duan, J., Cui, L., Yang, L., et al. (2019) Overexpression of UBR5 Promotes Tumor Growth in Gallbladder Cancer via PTEN/PI3K/Akt Signal Pathway. Journal of Cellular Biochemistry, 120, 11517-11524. [Google Scholar] [CrossRef] [PubMed]
[22] O’Brien, P.M., Davies, M.J., Scurry, J.P., Smith, A.N., Barton, C.A., Hen-derson, M.J., et al. (2008) Erratum: The E3 Ubiquitin Ligase EDD Is an Adverse Prognostic Factor for Serous Epithelial Ovarian Cancer and Modulates Cisplatin Resistance in Vitro. British Journal of Cancer, 98, 1085-1093. [Google Scholar] [CrossRef] [PubMed]
[23] Bradley, A., Zheng, H., Ziebarth, A., Sakati, W., Branham-O’Connor, M., Blumer, J.B., et al. (2014) EDD Enhances Cell Survival and Cisplatin Resistance and Is a Therapeutic Target for Ep-ithelial Ovarian Cancer. Carcinogenesis, 35, 1100- 1109. [Google Scholar] [CrossRef] [PubMed]
[24] Matsuura, K., Huang, N.J., Cocce, K., Zhang, L. and Kornbluth, S. (2016) Downregulation of the Proapoptotic Protein MOAP-1 by the UBR5 Ubiquitin Ligase and Its Role in Ovarian Cancer Resistance to Cisplatin. Oncogene, 36, 1698- 1706. [Google Scholar] [CrossRef] [PubMed]
[25] Song, M., Yeku, O.O., Rafiq, S., Purdon, T., Dong, X., Zhu, L., et al. (2020) Tumor Derived UBR5 Promotes Ovarian Cancer Growth and Metastasis through Inducing Immunosuppressive Macrophages. Nature Communications, 11, Article No. 6298. [Google Scholar] [CrossRef] [PubMed]
[26] Sun, J., Yang, X., Zhang, R., Liu, S., Gan, X., Xi, X., et al. (2017) GOLPH3 Induces Epithelial-Mesenchymal Transition via Wnt/β-Catenin Signaling Pathway in Epithelial Ovarian Cancer. Cancer Medicine, 6, 834-844. [Google Scholar] [CrossRef] [PubMed]

为你推荐